Neonatal Septicemia Caused by Edwardsiella Tarda: A Case Report and Literature Review

Why It Matters

Early recognition of this uncommon gram‑negative bacteremia enables targeted therapy, reducing mortality risk in vulnerable newborns and informing pediatric infectious‑disease protocols.

Key Takeaways

• Neonatal *E. tarda* septicemia identified in 5‑day‑old infant
• Blood culture confirmed pathogen; meropenem plus gamma globulin cured patient
• Infection lacks distinct signs compared with other gram‑negative sepsis
• Exposure to contaminated water or seafood is key diagnostic clue
• Early targeted therapy prevents complications in rare neonatal bacteremia

Pulse Analysis

Edwardsiella tarda is a gram‑negative rod most commonly associated with fish and amphibian infections, yet human cases are uncommon and neonatal involvement is exceedingly rare. The pathogen’s ability to survive in fresh‑water environments means that infants with indirect exposure—through contaminated water, raw seafood, or household pets—may acquire bacteremia without obvious gastrointestinal symptoms. Because only a handful of neonatal E. tarda septicemia reports exist in the literature, clinicians often overlook it in the differential diagnosis of early‑onset sepsis, potentially delaying appropriate therapy.

Diagnosing E. tarda septicemia relies on timely blood culture, as clinical presentation mirrors that of other gram‑negative organisms—jaundice, poor feeding, and irritability—without pathognomonic clues. In the reported case, a five‑day‑old infant presented with skin jaundice and reduced milk intake, prompting culture that yielded the organism. A thorough environmental history, including recent contact with ponds, aquariums, or raw fish dishes, can raise suspicion and expedite laboratory testing. Early identification is critical because empirical regimens for neonatal sepsis may not cover E. tarda’s variable susceptibility profile.

Therapeutic success in the case hinged on meropenem combined with intravenous gamma globulin, reflecting current recommendations for severe gram‑negative neonatal sepsis and the potential benefit of immunomodulation. Meropenem offers broad coverage against resistant Enterobacteriaceae, while immunoglobulin may neutralize endotoxins and support the immature immune system. The infant’s uneventful recovery and normal follow‑up underscore that prompt, targeted antimicrobial therapy can avert mortality and long‑term sequelae even in rare infections. Raising awareness of E. tarda among pediatric infectious‑disease specialists will improve early recognition and guide optimal treatment protocols.